Plastic surgical delivery systems for targeted gene therapy

Annals of Plastic Surgery

Volumn 60, Issue 3, 2008, Pages 323-332

  Ghali, Shadi ^a   Dempsey, Marlese P ^a   Jones, Deirdre M ^a   Grogan, Raymond H ^a   Butler, Peter E ^b   Gurtner, Geoffrey C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Delivery systems; Microvascular free flaps; Targeted gene therapy

Indexed keywords

VIRUS DNA;

ECHOGRAPHY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; INSTRUMENTATION; METHODOLOGY; PLASMID; PLASTIC SURGERY; REVIEW; TRANSGENE; WOUND HEALING;

DNA, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; PLASMIDS; RECONSTRUCTIVE SURGICAL PROCEDURES; SURGICAL FLAPS; TRANSGENES; ULTRASONOGRAPHY; WOUND HEALING;

EID: 44849098712     PISSN: 01487043     EISSN: 15363708     Source Type: Journal    
DOI: 10.1097/SAP.0b013e31806917b0     Document Type: Article

References (104)

1. Miller AD. Human gene therapy comes of age. Nature. 1992;357: 455- 460.
2. Culver KW, Anderson WF, Blaese RM. Lymphocyte gene therapy. Hum Gene Ther. 1991;2:107-109.
3. Blaese RM. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency. Pediatr Res. 1993;33(1 suppl):S49- 53; discussion S53-45.
4. Wiley Gene Therapy Clinical Trial Database. Available at: http:// www.wiley.co.uk/wileychi/genmed/clinical.
5. Lyngstadaas A. Status and potential of gene therapy in clinical medicine: assessment of an emerging health technology through systematic survey of clinical gene therapy protocols and published results. Int J Technol Assess Health Care. 2002;18:645- 674.
6. Johnson-Saliba M, Jans DA. Gene therapy: optimising DNA delivery to the nucleus. Curr Drug Targets. 2001;2:371-399.
7. Rubin J, Galanis E, Pitot HC, et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 1997;5: 419-425.
8. Porteous DJ, Dorin JR, McLachlan G, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997; 3:210 -218.
9. Kircheis R, Wightman L, Schreiber A, et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 2001;1:28-40.
10. Olivares EC, Hollis RP, Chalberg TW, et al. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol. 2002;11:1124 -1128.
11. Jenke AC, Eisenberger T, Baiker A, et al. The nonviral episomal replicating vector pEPI-1 allows long-term inhibition of bcr-abl expression by shRNA. Hum Gene Ther. 2005;4:533-539.
12. Norman J, Denham W, Denham D, et al. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000; 16:1425-1430.
13. Li S, Wu SP, Whitmore M, et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol. 1999;76(5 pt 1):L796-804.
14. Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta. 1997;1329:345-356.
15. Chen S, Shohet RV, Bekeredjian R, et al. Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasound-targeted microbubble destruction. J Am Coll Cardiol. 2003;42:301-308.
16. Nishi T, Yoshizato K, Yamashiro S, et al. High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res. 1996;56:1050 -1055.
17. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A. 1999;96:6417- 6422.
18. Sakai M, Nishikawa M, Thanaketpaisarn O, et al. Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Ther. 2005;7:607- 616.
19. Azuma H, Tomita N, Kaneda Y, et al. Transfection of NFkappaBdecoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther. 2003;5:415- 425.
20. Anwer K, Kao G, Proctor B, et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther. 2000;21:1833-1839.
21. Yamashita Y, Shimada M, Tachibana K, et al. In vivo gene transfer into muscle via electro-sonoporation. Hum Gene Ther. 2002;13:2079- 2084.
22. Lauterbach H, Gruber A, Ried C, et al. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. J Immunol. 2006;176:4600-4607.
23. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 1993;10:5911-5921.
24. Balicki D, Beutler E. Gene therapy of human disease. Medicine (Baltimore). 2002;81:69-86.
25. Evans CH, Ghivizzani SC, Oligino TA, et al. Future of adenoviruses in the gene therapy of arthritis. Arthritis Res. 2001;3:142-146.
26. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320 -1323.
27. Romano G, Claudio PP, Kaiser HE, et al. Recent advances, prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy. In Vivo. 1998;12:59-67.
28. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999;5:440-447.
29. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407- 4411.
30. Yang Y, Li Q, Ertl HC, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69:2004 -2015.
31. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998;2:180 -183.
32. Kochanek S. High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther. 1999;10:2451-2459.
33. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication- competent adenoviruses. Hum Gene Ther. 1998;9:1909-1917.
34. Schiedner G, Hertel S, Johnston M, et al. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol. 2002;76: 1600-1609.
35. Powell SK, Kaloss M, Burimski I, et al. In vitro analysis of transformation potential associated with retroviral vector insertions. Hum Gene Ther. 1999;10:2123-2132.
36. Purcell DF, Broscius CM, Vanin EF, et al. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol. 1996;70:887- 897.
37. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
38. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410 -2413.
39. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415- 419.
40. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;1:56-63.
41. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;1:64 -70.
42. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158: 97-129.
43. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005; 3:321-328.
44. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A. 1990;87:2211-2215.
45. Duan D, Sharma P, Dudus L, et al. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol. 1999;73:161-169.
46. Nakai H, Iwaki Y, Kay MA, et al. Isolation of recombinant adenoassociated virus vector-cellular DNA junctions from mouse liver. J Virol. 1999;73:5438 -5447.
47. Miao CH, Snyder RO, Schowalter DB, et al. The kinetics of rAAV integration in the liver. Nat Genet. 1998;1:13-15.
48. Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol. 2000;74:3793-3803.
49. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002;12:967-978.
50. Burton EA, Glorioso JC. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors. Drug Discov Today. 2001;6:347-356.
51. Martino G, Poliani PL, Marconi PC, et al. Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type- 1-derived vectors. Gene Ther. 2000;13:1087-1093.
52. Burton EA, Glorioso JC, Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Ther. 2003;20:1721-1727.
53. Glorioso JC, Mata M, Fink DJ. Gene therapy for chronic pain. Curr Opin Mol Ther. 2003;5:483- 488.
54. Fink DJ, Glorioso JC. Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med. 1997;3:357-359.
55. Bowers WJ, Olschowka JA, Federoff HJ. Immune responses to replication- defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther. 2003;11:941-945.
56. Cui Y, Golob J, Kelleher E, et al. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood. 2002;99:399-408.
57. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85: 221-228.
58. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokineinduced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;4:434-438.
59. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103: 1231-1236.
60. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004;287:C572-579.
61. Edelberg J, Tang L, Hattori K, et al. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002;90:E89 -93.
62. Zhang ZG, Zhang L, Jiang Q, et al. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res. 2002;90:284 -288.
63. Hess DC, Hill WD, Martin-Studdard A, et al. Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke. Stroke. 2002;33:1362-1368.
64. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000;87:728 -730.
65. Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. 2002;6:607- 612.
66. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow- derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;11:1194 -1201.
67. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation. 2002;105:732-738.
68. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005;387(pt 1):1-15.
69. Evans TR, Keith WN. Intra-peritoneal administration of genetic therapies: promises and pitfalls. Minerva Ginecol. 2004;56:529 -538.
70. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244 -2245.
71. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002;12:979- 986.
72. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther. 2002;13:15- 63.
73. Crystal RG, Harvey BG, Wisnivesky JP, et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002;13:65-100.
74. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738 -746.
75. Liechty KW, Sablich TJ, Adzick NS, et al. Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing. Wound Repair Regen. 1999;3:148 -153.
76. Crombleholme TM. Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen. 2000;6:460-472.
77. Liechty KW, Nesbit M, Herlyn M, et al. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol. 1999;113:375-383.
78. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen. 2000;6:480-493.
79. Margolis DJ, Cromblehome T, Herlyn M, et al. Clinical protocol: phase I trial to evaluate the safety of H5020CMV. PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A. Hum Gene Ther. 2004;10:1003-1019.
80. Strickland J. Flexor tendons-acute injuries. In: Pederson W, ed. Green's Operative Hand Surgery. Philadelphia, PA: Churchill Livingstone; 1999:1854.
81. Lawrence W, Kashyap A. Healing of nerves, blood vessels, muscle, tendon, cartilage and bone. In: Vander Kolk C, ed. Plastic Surgery: Indications, Operations and Outcomes. Vol 1. Missouri: Mosby Inc; 2000:79 -96.
82. Gerich TG, Kang R, Fu FH, et al. Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. Gene Ther. 1996;12:1089 -1093.
83. Lou J, Tu Y, Burns M, et al. BMP-12 gene transfer augmentation of lacerated tendon repair. J Orthop Res. 2001;6:1199 -1202.
84. Munro A. Head and Neck cancer. 3rd ed. London, UK: Chapman and Hall; 1995.
85. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res.1995;55:1- 6.
86. Clayman GL, Frank DK, Bruso PA, et al. Adenovirus-mediated wildtype p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999;7:1715-1722.
87. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;9:1016- 1027.
88. Wilson JM. Gendicine: the first commercial gene therapy product. Hum Gene Ther. 2005;9:1014 -1015.
89. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;3:798- 806.
90. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19: 289-298.
91. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;8:879-885.
92. Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920 -926.
93. Chang SC, Chuang HL, Chen YR, et al. Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration. Gene Ther. 2003;24:2013-2019.
94. Breitbart AS, Grande DA, Mason JM, et al. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg. 1999;5:488-495.
95. Young RG, Butler DL, Weber W, et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res. 1998;4: 406-413.
96. Taub PJ, Marmur JD, Zhang WX, et al. Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. Plast Reconstr Surg. 1998;6:2033-2039.
97. Lubiatowski P, Goldman CK, Gurunluoglu R, et al. Enhancement of epigastric skin flap survival by adenovirus-mediated VEGF gene therapy. Plast Reconstr Surg. 2002;6:1986 -1993.
98. Asahara T, Kalka C, Isner JM. Stem cell therapy and gene transfer for regeneration. Gene Ther. 2000;7:451- 457.
99. Tepper OM, Mehrara BJ. Gene therapy in plastic surgery. Plast Reconstr Surg. 2002;109:716 -734.
100. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model: immunosuppression with TGF-beta 1 or vIL-10. Transplantation. 1995;59:809- 816.
101. Shaked A, Csete ME, Drazan KE, et al. Adenovirus-mediated gene transfer in the transplant setting, II: successful expression of transferred cDNA in syngeneic liver grafts. Transplantation. 1994;57:1508 -1511.
102. Ardehali A, Reddy R, Laks H. Gene therapy and heart transplantation. Expert Opin Investig Drugs. 2000;5:1021-1027.
103. Michaels JT Dobryansky M, Galiano RD, et al. Ex vivo transduction of microvascular free flaps for localized peptide delivery. Ann Plast Surg. 2004;52:581-584.
104. Michaels JV, Levine JP, Hazen A, et al. Biologic brachytherapy: ex vivo transduction of microvascular beds for efficient, targeted gene therapy. Plast Reconstr Surg. 2006;118:54-65; discussion 66-68.